By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
How to watch NASA's Artemis 2 astronauts launch to the moon on April 1 - 2'Malcolm in the Middle' reboot releases 1st trailer, reuniting Frankie Muniz and Bryan Cranston: Watch here
- 3Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
- 4Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- 5Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- Texas cities have some of the highest preterm birth rates in the US, highlighting maternal health crisis nationwide
- Noctourism: the new safari travel trend that's changing the wildlife we can photograph in Africa
- Director of Swiss hospital describes the rush to treat the injured from Alpine resort bar fire
- Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- Melodic Combination d: A Survey of \Unrecorded Music Energy\ Show
- Little Italy Mercato brings fresh food and community to downtown San Diego
- How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- Vote in favor of the wide open action that revives your brain and soul!
- Germany records first wolf bite on human since repopulation
